US20120251502A1
Inventor : Jonathan S. TownerStuart T. NicholJames A. ComerThomas G. KsiazekPierre E. Rollin
Current Assignee US Department of Health and Human Services (HHS) Centers of Disease Control and Prevention (Department of Health and Human Services)
Worldwide applications
2009 EP EP CA US WO AU 2015 US 2017 US
Application US13/125,890 events:
2008-10-24 - Priority to US10817508P
2009-10-26 - Application filed by US Department of Health and Human Services (HHS)
2009-10-26 Priority to US13/125,890
2009-10-26 - Priority to PCT/US2009/062079
2011-04-25 - Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
2012-10-04 - Publication of US20120251502A1
2019-02-17 - Application status is Abandoned
Abstract
Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
Classifications
C12N7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
A61K39/12 Viral antigens
C07K14/005 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C07K16/10 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
C12Q1/701 Specific hybridization probes
G01N33/56983 Viruses
A61K2039/5254 Virus avirulent or attenuated
A61K2039/5256 Virus expressing foreign proteins
A61K2039/53 DNA (RNA) vaccination
A61K2039/542 Mucosal route oral/gastrointestinal
A61K2039/543 Mucosal route intranasal
A61K39/00 Medicinal preparations containing antigens or antibodies
C07K2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C12N2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14143 Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
C12N2760/14145 Special targeting system for viral vectors
C12N2810/6072 Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
G01N2333/08 RNA viruses
Inventor : Jonathan S. TownerStuart T. NicholJames A. ComerThomas G. KsiazekPierre E. Rollin
Current Assignee US Department of Health and Human Services (HHS) Centers of Disease Control and Prevention (Department of Health and Human Services)
Worldwide applications
2009 EP EP CA US WO AU 2015 US 2017 US
Application US13/125,890 events:
2008-10-24 - Priority to US10817508P
2009-10-26 - Application filed by US Department of Health and Human Services (HHS)
2009-10-26 Priority to US13/125,890
2009-10-26 - Priority to PCT/US2009/062079
2011-04-25 - Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
2012-10-04 - Publication of US20120251502A1
2019-02-17 - Application status is Abandoned
Abstract
Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
Classifications
C12N7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
A61K39/12 Viral antigens
C07K14/005 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C07K16/10 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
C12Q1/701 Specific hybridization probes
G01N33/56983 Viruses
A61K2039/5254 Virus avirulent or attenuated
A61K2039/5256 Virus expressing foreign proteins
A61K2039/53 DNA (RNA) vaccination
A61K2039/542 Mucosal route oral/gastrointestinal
A61K2039/543 Mucosal route intranasal
A61K39/00 Medicinal preparations containing antigens or antibodies
C07K2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C12N2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14143 Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
C12N2760/14145 Special targeting system for viral vectors
C12N2810/6072 Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
G01N2333/08 RNA viruses
